Skip to main content
. 2018 May 29;9(41):26353–26369. doi: 10.18632/oncotarget.25293

Figure 7. Residual CLL cells and T cells post LDC526 treatment express high levels of BCL-2.

Figure 7

(A) Representative histograms of intracellular anti-Bcl-2 and corresponding isotype control staining of TCL1 CLL cells (CD5+CD19+) and T cells (CD5+CD19-). (B) Graphs comparing the CLL and T cell intracellular Bcl-2 expression of individual mice on days -5 and +3. The Bcl-2 expression was quantified as median fluorescence intensity ratio (MFI ratio: MFI anti-Bcl-2/MFI isotype control antibody). * p<0.05.